AUROBINDO PHARMA LIMITED has announced the subscription of 10,000 equity shares in its subsidiary, A1 Biochem USA Inc., for a total of USD 1,000,000. This acquisition marks the establishment of a new subsidiary in the USA, which will focus on Contract Research and Development services. The move is part of a broader acquisition of the A1 Biochem Group, previously disclosed in July 2026.
AUROBINDO PHARMA Expands US Operations with New Subsidiary Acquisition
AUROBINDO PHARMA LIMITED has completed a significant step in its strategic expansion by subscribing to 10,000 equity shares of its U.S.-based subsidiary, A1 Biochem USA Inc. Each share was valued at USD 100, with the total investment amounting to USD 1,000,000. This transaction, finalized on September 11, 2026, establishes A1 Biochem USA Inc. as a wholly-owned subsidiary within the AUROBINDO PHARMA group.
Strategic Rationale and Business Focus
The primary objective for this newly acquired subsidiary is to engage in the Contract Research and Development services business. This initiative is a continuation of the larger acquisition of the A1 Biochem Group, which was initially announced on July 23, 2026. The establishment of this U.S.-based entity is aimed at broadening the company’s service offerings and geographic reach within the global pharmaceutical R&D landscape.
Background of A1 Biochem USA Inc.
A1 Biochem USA Inc. was officially incorporated in the United States on August 27, 2026. It is structured as a wholly-owned subsidiary of A1 Biochem Labs (India) Private Limited, which itself is a subsidiary of Apitoria Pharma Private Limited, ultimately owned by AUROBINDO PHARMA LIMITED. The company is in its nascent stages, with no prior operational history or turnover to report.
Acquisition Details
The consideration for this acquisition was settled entirely in cash, totaling USD 1,000,000 for the initial subscription share capital. AUROBINDO PHARMA LIMITED now holds 100% of the shareholding in A1 Biochem USA Inc. No specific governmental or regulatory approvals were required for this particular transaction, and the integration is considered complete, with no indicative timeline needed for completion.
Source: BSE
